Clinical trial NCT00622752: Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes
Official title: A Double-Blind, Randomized, Placebo- and NRT -Controlled Phase II Study to Assess the Effects of EVT 302 Alone and in Combination With NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Smoking Cessation
Keywords: Smoking cessation
Craving
Smokers
Lead sponsor: Evotec International GmbH
Sponsor class: INDUSTRY
First posted: 2008-02-25
Enrollment: 90
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This randomised, placebo-controlled study is designed to explore the effects of EVT 302 both with and without concomitant nicotine replacement therapy (NRT) on craving and withdrawal in smokers after short term deprivation of cigarettes.


Eligibility criteria: Inclusion Criteria:

* Male subjects between 18 and 55 years of age, inclusive
* BMI between 18 and 30, minimum weight of 50 kg
* Negative urine drug \& alcohol screen
* Able to comply with tyramine-restricted diet
* Smoking of ≥17 and ≤34 cigarettes per day for the past year and have not tried to quit smoking in the 3 months prior to screening
* Subjects are willing and able to quit for about 12 hours in each of three subsequent study periods
* Previous experience of craving following smoking cessation
* Breath CO between 15 ppm and 20 ppm and cotinine in saliva and plasma at least 250 ng/mL at screening
* Liver function test results not above 1.5 times the upper normal limit (UNL) at screening visit and at re-assessment during the study.

Exclusion Criteria:

* Participation in another clinical study within 60 days of screening
* Evidence of active significant psychiatric or neurological disease or dependency other than cigarettes
* Are known to have or are a carrier of the hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, has a positive result to the human immunodeficiency virus-1 and/or 2 (HIV-1 and/or HIV-2) antibodies
* Known hypersensitivity to MAO inhibitors or any substance that is contained in the study formulations
* Known allergy to plasters or NRT patches
* Previous participation in another study with EVT 302
* Currently receiving treatment for smoking cessation
* Current use of tobacco products other than cigarettes
* Require treatment with any medication
* Subject with a clinically relevant abnormal 12-lead ECG recording or QTcB/F \>430 ms
* Use of a prescription medicine within 14 days or 5 half-lives, whichever is the longer, of the start of dosing, or use of an over-the-counter medication during the 7 days before the study, including herbal remedies, but excluding paracetamol and vitamin supplements (provided intake does not exceed the daily recommended allowance)
* Subjects must not be planning to father a child or donate sperm, during the study and 3 months after the end of the study. Acceptable methods of contraception comprise barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least 2 month)
* Daily consumption of more than 5 cups of tea or coffee, or more than 1.0 litre of xanthine-containing drinks
* Recent myocardial infarction, unstable or worsening angina pectoris, prince metal angina, severe arrhythmias, recent stroke.
* Creatinine clearance (CLR) calculated according to the formula by Modification of Diet in Renal Disease (MDRD) of \<80 mL/min

Primary outcomes:
measure: Reduction in Craving and withdrawal
timeFrame: Within 12 hours of the last cigarette
Secondary outcomes:
measure: CogState Cognitive test Battery
timeFrame: 12 hours post last cigarette
measure: Breath carbon monoxide levels
timeFrame: 12 hours post last cigarette
measure: Salivary cotinine levels
timeFrame: 12 hours post last cigarette
measure: Clinical safety lab tests
timeFrame: Up to 7 days post dose
measure: Assessment of adverse events
timeFrame: Up to 7 days post dose
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: PAREXEL International GmbH, Clinical Pharmacology Research Unit
Study officials:
affiliation: Parexel International GmbH, Clinical Pharmacology Research Unit
name: Alla Radicke, MD
role: PRINCIPAL_INVESTIGATOR
References: